Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2006-10-31
2006-10-31
Padmanabhan, Sreeni (Department: 1616)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S434000, C424S450000, C514S853000
Reexamination Certificate
active
07128897
ABSTRACT:
Pharmaceutical compositions are described that contain one agent for treatment of sinusitis and a surfactant. The compositions are prepared to have a surface tension that renders the composition effective for treatment of sinusitis.
REFERENCES:
patent: 4312860 (1982-01-01), Clements
patent: 4424216 (1984-01-01), Cerami et al.
patent: 4438100 (1984-03-01), Balslev et al.
patent: 4468513 (1984-08-01), Kirst et al.
patent: 4478822 (1984-10-01), Haslam et al.
patent: 4486418 (1984-12-01), Watanabe et al.
patent: 4493831 (1985-01-01), Takaya et al.
patent: 4554269 (1985-11-01), Takaya et al.
patent: 4571334 (1986-02-01), Yoshida et al.
patent: 4593089 (1986-06-01), Wang et al.
patent: 4617293 (1986-10-01), Wahlig et al.
patent: 4647656 (1987-03-01), Watanabe et al.
patent: 4656160 (1987-04-01), Takaya et al.
patent: 4684643 (1987-08-01), Buddenbaum et al.
patent: 4693999 (1987-09-01), Axelsson et al.
patent: 4767612 (1988-08-01), Hagen et al.
patent: 4855287 (1989-08-01), Watanabe et al.
patent: 4906476 (1990-03-01), Radhakrishnan
patent: 4917951 (1990-04-01), Wallach
patent: 4944949 (1990-07-01), Story et al.
patent: 4950477 (1990-08-01), Schmitt et al.
patent: 5004611 (1991-04-01), Leigh
patent: 5006343 (1991-04-01), Benson et al.
patent: 5039666 (1991-08-01), Novick, Jr.
patent: 5049388 (1991-09-01), Knight et al.
patent: 5049389 (1991-09-01), Radhakrishnan
patent: 5110806 (1992-05-01), Clements
patent: 5112804 (1992-05-01), Kowarski
patent: 5141674 (1992-08-01), Leigh
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5167506 (1992-12-01), Kilis et al.
patent: 5169637 (1992-12-01), Lenk et al.
patent: 5299566 (1994-04-01), Davis et al.
patent: 5397771 (1995-03-01), Bechgaard et al.
patent: 5428006 (1995-06-01), Bechgaard et al.
patent: 5508269 (1996-04-01), Smith et al.
patent: 5512269 (1996-04-01), Molina y Vedia et al.
patent: 5522385 (1996-06-01), Lloyd et al.
patent: 5525329 (1996-06-01), Snyder et al.
patent: 5567716 (1996-10-01), Della Valle et al.
patent: 5595977 (1997-01-01), Dyrsting et al.
patent: 5614216 (1997-03-01), Janoff
patent: 5624962 (1997-04-01), Dyrsting et al.
patent: 5655523 (1997-08-01), Hodson et al.
patent: 5685291 (1997-11-01), Marsh
patent: 5693608 (1997-12-01), Bechgaard et al.
patent: 5789391 (1998-08-01), Jacobus et al.
patent: 5843881 (1998-12-01), Dubois et al.
patent: 5861275 (1999-01-01), Hansen
patent: 5883084 (1999-03-01), Peterson et al.
patent: 5900406 (1999-05-01), von Ahsen et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 5906198 (1999-05-01), Flickinger
patent: 5925334 (1999-07-01), Rubin et al.
patent: 5958897 (1999-09-01), Jacobus et al.
patent: 5972904 (1999-10-01), Jacobus et al.
patent: 5976573 (1999-11-01), Kim
patent: 5981506 (1999-11-01), Jacobus et al.
patent: 5985259 (1999-11-01), Cagle et al.
patent: 6083922 (2000-07-01), Montgomery
patent: 6126930 (2000-10-01), Dubois et al.
patent: 6143329 (2000-11-01), Kim
patent: 6207703 (2001-03-01), Ponikau
patent: 6241969 (2001-06-01), Saidi et al.
patent: 6274634 (2001-08-01), Yasueda et al.
patent: 6277855 (2001-08-01), Yerxa
patent: 6291500 (2001-09-01), Ponikau
patent: 6331529 (2001-12-01), Yerxa et al.
patent: 6375984 (2002-04-01), Kan
patent: 6387886 (2002-05-01), Montgomery et al.
patent: 6395300 (2002-05-01), Straub et al.
patent: 6395746 (2002-05-01), Cagle et al.
patent: 6420347 (2002-07-01), Jacobus et al.
patent: 6423694 (2002-07-01), Drutz et al.
patent: 6436910 (2002-08-01), Yerxa et al.
patent: 6448276 (2002-09-01), Yerxa
patent: 6462183 (2002-10-01), Toth et al.
patent: 6555566 (2003-04-01), Ponikau
patent: 2001/0002400 (2001-05-01), Ponikau
patent: 2001/0006944 (2001-07-01), Ponikau
patent: 2001/0031779 (2001-10-01), Ponikau
patent: 2002/0052338 (2002-05-01), Yerxa et al.
patent: 2002/0052390 (2002-05-01), Ponikau
patent: 2002/0061281 (2002-05-01), Osbakken et al.
patent: 2002/0065244 (2002-05-01), Yerxa et al.
patent: 2002/0102294 (2002-08-01), Bosch et al.
patent: 2002/0103157 (2002-08-01), Yerxa et al.
patent: 0 267 050 (1988-05-01), None
patent: 0 267 050 (1994-09-01), None
patent: 0626173 (1994-11-01), None
patent: 0507707 (1995-07-01), None
patent: 0470154 (1996-06-01), None
patent: 0563131 (1996-09-01), None
patent: 0682514 (2001-09-01), None
patent: 0925308 (2002-06-01), None
patent: 0705614 (2002-09-01), None
patent: 10130148 (1998-05-01), None
patent: 9729756 (1997-08-01), None
patent: 9735591 (1997-10-01), None
patent: 9834593 (1998-08-01), None
patent: 0000181 (2000-01-01), None
patent: 0050024 (2000-08-01), None
patent: 01/02024 (2001-01-01), None
patent: 0119344 (2001-03-01), None
patent: 0180844 (2001-11-01), None
patent: 02068031 (2002-09-01), None
patent: WO 03/020219 (2003-03-01), None
Drug Information Handbook, by Lexi-comp, 1993, pp. 23-24 and 676.
Alexandrakis et al., “Nasolacrimal Duct Obstruction and Orbital Cellulitis Associated With Chronic Intranasal Cocaine Abuse,”Arch. Ophthalmol. 117: 1617-1622 (1999).
Baraniuk et al., “Addition of intranasal glucocortcoids to standard antibiotic therapy for sinusitis”,Current Allergy and Asthma Rep 1(3): 191-2 (May, 2001).
Boyce et al., “MRSA patients: proven methods to treat colonization and infecion,”Journal of Hospital Infection 48(Supplement A): S9-S14 (2001).
Certified English Translation for Japanese Patent Application (Kokai) No. 10-130148 entitled: “Composition for Nebulizers”.
Cimochowski et al., “Intranasal Mupirocin Reduces Sternal Wound Infection After open Heart Surgery in Diabetics and Nondiabetics,”Ann. Thorac. Surg. 71: 1572-9 (2001).
Derwent# 009206491, W.P.I. Acc No.: 1992-333912/199241, for European Patent Application, EP 507707 A, “Control unit for therapeutic nebuliser—has sonic vibration control chamber made separate from over-pressure control chamber and linked to pulsed air source”.
Derwent# 013773627, W.P.I. Acc No.: 2001-257838/200126, for PCT Patent Application, WO 200119344 A1, “Preparing powders for nasal atomization, useful e.g. for administering Vitamin B12, using water insoluble, absorbent excipient to carry active ingredient”.
Desrosiers et al., “Treatment of chronic rhinosinusutus refractory to other treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: Results of a controlled trial,”Otolaryngol Head Neck Surg 125: 265-9 (2001).
Desrosiers et al., “Treatment of Failures of Endoscopic Sinus Surgery (ESS) with Topical Antibiotics Delivered by Large-Diameter Particle Aerosol Therapy,” ENT Academy Meeting (May 1999).
Dolor et al., “Comparison of Cefuroxime With or Without Intranasal Fluticasone for the Treatment of Rhinosinusitis,”Journal of the American Medical Association 286: 3097-3105 (2001).
Dunbar, C.A. and A.J. Hickey, “Evaluation of Probability Density Functions To Approximate Particle Size Distributions of Representative Pharmaceutical Aerosols,”J. Aerosol. Sci 31(7): 813-831 (2000).
Farr, B.M., “Mupirocin to Prevent S.AureusInfections,”New England Journal of Medicine 346(24): 1905-1906 (2002).
Guevara et al., “Ambulatory Aerosol Therapy in the Treatment of Chronic Pathology in O.R.L. Sphere,”Annales O.R.L. Iber.Amer. XVIII, 3:231-238 (1991).
Hiramatsu et al., “MRSA Infections in an Intensive Care Unit,” Masui 49: 867-71 (2000).
Hitomi et al. “Control of a methicillin-resistantStaphylococcus aureusoutbreak in a neonatal intensive care unit by unselective use of nasal mupirocin ointment,”Journal of Hospital Infection 46: 123-129 (2000).
Holmström, M., “Nasal polyposis—of interest to several specialities. Improvements in diagnosis and new treatment methods,”Lakartidningen 97(34): 3611-5 (2000).
Jeong et al., “Intranasal mupirocin for prevention of hospital MRSA infection,”ASHP-Midyear Clinical Meeting, Abstract of Meeting Presentation 33(Dec): INTL-21 (1998).
Kaiser et al., “Impact of Zanamivir on Antibiotic Use for Respiratory Events Following Acute Influenz
Hale Mary Anne
Leivo Frederick T.
Munk James D.
Osbakken Robert S.
Haghighatian Mina
Naryx Pharma, Inc.
Padmanabhan Sreeni
Wilson Sonsini Goodrich & Rosati
LandOfFree
Aerosolized anti-infectives, anti-inflammatories, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aerosolized anti-infectives, anti-inflammatories, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aerosolized anti-infectives, anti-inflammatories, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3714805